Back to News
Market Impact: 0.35

Earnings call transcript: Inission Q2 2026 sales rise 18.7% as stock jumps 9.1%

GAP
LMDCF
TGT
Corporate EarningsCompany FundamentalsCorporate Guidance & OutlookMarket Technicals & FlowsEnergy Markets & Prices
Earnings call transcript: Inission Q2 2026 sales rise 18.7% as stock jumps 9.1%

Inission reported Q2 2026 sales of SEK 635M (+18.7% YoY; 7.4% organic) and EBITDA of SEK 41M (+~70% YoY), lifting the EBITDA margin to 6.4% from 4.5%. EPS doubled to SEK 1.3 and management guided Q2/H2 run-rate of SEK 210–220M per month while keeping full-year sales guidance at SEK 2.3B–2.5B, confident of reaching the upper end. The stock rose 9.12% to $74.20, with investors focused on improving profitability and maintained visibility despite noted supply-chain and inventory risks.

Analysis

This is a margin-inflection story more than a growth story. If the current run-rate holds, the real winner is not just one Swedish assembler but the broader Nordic mid-cap EMS complex: names with regional production, tighter customer niches, and operating leverage should see the fastest EPS upgrades, while larger incumbents may face multiple pressure if investors rotate toward the names with the steepest incremental margin slope. The secondary effect is on the supply chain: PCB/component vendors and nearby logistics providers can see a temporary pull-forward in demand, but inventory pre-buys can reverse quickly once lead times normalize.

The key risk is that the market is extrapolating a clean H2 into a still-cyclical business. The thesis breaks if monthly sales slip below the implied cadence or if margin stalls below the 7% level; in that case this re-rates as a classic working-capital story rather than a durable operating-improvement story. Leverage is not a near-term problem, but it matters because any inventory unwind would hit cash conversion before it shows up in reported EPS. The data-breach issue is probably non-financial unless a broader trust or remediation problem emerges later.

Consensus may be underestimating how much of the margin improvement comes from mix and fixed-cost absorption rather than one-off recovery. That argues for trading this on pullbacks, not chasing a gap-up after a strong print, because the stock already looks like it is pricing in a decent amount of H2 execution. The contrarian view is that the market may also be overrating the defense angle: helpful, yes, but lumpy and timing-sensitive, so it should support valuation rather than justify a full rerating on its own.